Pulmonary multifunctional nano-oncological modules for lung cancer treatment and prevention

Journal of Biomedical Nanotechnology

Volumn 10, Issue 9, 2014, Pages 1863-1893

  Shete, Harshad K ^a   Vyas, Swati S ^a   Patravale, Vandana B ^a   Disouza, John I ^b  

^a INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

^b Tatyasaheb Kore College of Pharmacy Warananagar   (India)

Author keywords

Lung cancer; Metastasis; Nano Oncological modules; Nanoparticles; Pulmonary delivery

Indexed keywords

CELL MEMBRANES; CYTOLOGY; DISEASES; ENZYME ACTIVITY; NANOPARTICLES; PATHOLOGY;

COMPLICATED STRUCTURES; ENZYMATIC DEGRADATION; LUNG CANCER; MEMBRANE TRANSLOCATION; METASTASIS; NANO-ONCOLOGICAL MODULES; PULMONARY DELIVERY; THERAPEUTIC EFFICACY;

BIOLOGICAL ORGANS;

ALUMINUM OXIDE; ANTINEOPLASTIC AGENT; CALCIUM PHOSPHATE; CARBON NANOTUBE; CYCLODEXTRIN; DENDRIMER; GOLD NANOPARTICLE; LIPID COATED CALCIUM PHOSPHATE NANOPARTICLE; LIPOPLEX; LIPOSOME; NANOCARRIER; NANOHORN; NANOMATERIAL; NANOSPONGE; NANOSTRUCTURED LIPIDIC CARRIER; SILVER NANOPARTICLE; SOLID LIPID NANOPARTICLE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; UNCLASSIFIED DRUG; NANOPARTICLE;

CANCER MORTALITY; CELL MEMBRANE TRANSPORT; CELL NUCLEUS; DRUG DELIVERY SYSTEM; DRY POWDER INHALER; ENDOSOME; ENZYMATIC DEGRADATION; HUMAN; LUNG ALVEOLUS MACROPHAGE; LUNG CANCER; LUNG FLUID; METASTASIS; METERED DOSE INHALER; MICELLE; MUCUS; NANOTECHNOLOGY; NEBULIZER; REVIEW; SOFT MIST INHALER; TREATMENT OUTCOME; ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; DRUG ADMINISTRATION ROUTE; LUNG; LUNG NEOPLASMS; PATHOLOGY;

ANIMALS; DRUG ADMINISTRATION ROUTES; DRUG DELIVERY SYSTEMS; HUMANS; LUNG; LUNG NEOPLASMS; MODELS, BIOLOGICAL; NANOPARTICLES;

EID: 84904858553     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2014.1900     Document Type: Review

References (276)

1. K. M. Kerr, Pulmonary preinvasive neoplasia. J. Clin. Pathol. 54, 257 (2001).
2. H. M. Courrier, N. Butz, and T. F. Vandamme, Pulmonary drug delivery systems: Recent developments and prospects. Crit. Rev. Ther. Drug Carrier Syst. 19, 425 (2002).
3. D. A. Groneberg, C. Witt, U. Wagner, K. F. Chung, and A. Fischer, Fundamentals of pulmonary drug delivery. Respir. Med. 97, 382 (2003).
4. J. S. Patton and P. R. Byron, Inhaling medicines: Delivering drugs to the body through the lungs. Nat. Rev. Drug Discov. 6, 67 (2007).
5. J. Hukkanen, O. Pelkonen, J. Hakkola, and H. Raunio, Expression and regulation of xenobiotic-metabolizing cytochrome P450 (CYP) enzymes in human lung. Crit. Rev. Toxicol. 32, 391 (2002).
6. M. Geiser, Update on macrophage clearance of inhaled micro- and nanoparticles. J. Aerosol Med. Pulm. Drug Deliv. 23, 207 (2010).
7. F. Andrade, D. Rafael, M. Videira, D. Ferreira, A. Sosnik, and B. Sarmento, Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases. Adv. Drug Deliv. Rev. 65, 1816 (2013).
8. N. Islam and M. J. Cleary, Developing an efficient and reliable dry powder inhaler for pulmonary drug delivery - a review for multidisciplinary researchers. Med. Eng. Phys. 34, 409 (2012).
9. H. Shete, R. Prabhu, and V. Patravale, Endosomal escape: A bottleneck in intracellular delivery. J. Nanosci. Nanotechnol. 14, 460 (2013).
10. J. K. Lam, W. Liang, and H. K. Chan, Pulmonary delivery of therapeutic siRNA. Adv. Drug Deliv. Rev. 64, 1 (2012).
11. A. S. Jain, S. M. Shah, M. S. Nagarsenker, Y. Nikam, R. P. Gude, F. Steiniger, J. Thamm, and A. Fahr, Lipid colloidal carriers for improvement of anticancer activity of orally delivered quercetin: Formulation, characterization and establishing in vitro-in vivo advantage. J. Biomed. Nanotechnol. 9, 1230 (2013).
12. M. L. Jugan, S. Barillet, A. Simon-Deckers, S. Sauvaigo, T. Douki, N. Herlin, and M. Carriere, Cytotoxic and genotoxic impact of TiO2 nanoparticles on A549 cells. J. Biomed. Nanotechnol. 7, 22 (2011).
13. D. Wehrung, L. Bi, W. J. Geldenhuys, and M. O. Oyewumi, Antitumor efficacy and tolerability of systemically administered gallium acetylacetonate-loaded gelucire-stabilized nanoparticles. J. Biomed. Nanotechnol. 9, 1029 (2013).
14. D. Wehrung and M. O. Oyewumi, Antitumor effect of novel gallium compounds and efficacy of nanoparticle-mediated gallium delivery in lung cancer. J. Biomed. Nanotechnol. 8, 161 (2012).
15. M. Singh, P. Bhatnagar, A. K. Srivastava, P. Kumar, Y. Shukla, and K. C. Gupta, Enhancement of cancer chemosensitization potential of cisplatin by tea polyphenols poly(lactide-co-glycolide) nanoparticles. J. Biomed. Nanotechnol. 7, 202 (2011).
16. Y. Y. Guan, X. Luan, J. R. Xu, Y. R. Liu, Q. Lu, C. Wang, H. J. Liu, Y. G. Gao, H. Z. Chen, and C. Fang, Selective eradication of tumor vascular pericytes by peptide-conjugated nanoparticles for antiangiogenic therapy of melanoma lung metastasis. Biomaterials 35, 3060 (2014).
17. C. Godugu, A. R. Patel, R. Doddapaneni, S. Marepally, T. Jackson, and M. Singh, Inhalation delivery of Telmisartan enhances intratumoral distribution of nanoparticles in lung cancer models. J. Control. Release. 172, 86 (2013).
18. M. Videira, A. J. Almeida, and A. Fabra, Preclinical evaluation of a pulmonary delivered paclitaxel-loaded lipid nanocarrier antitumor effect. Nanomedicine 8, 1208 (2012).
19. O. Taratula, O. B. Garbuzenko, A. M. Chen, and T. Minko, Innovative strategy for treatment of lung cancer: Targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA. J. Drug Target 19, 900 (2011).
20. C. Li, H. T. Nguyen, Y. Zhuang, Z. Lin, E. K. Flemington, Y. Zhuo, S. P. Kantrow, G. F. Morris, D. E. Sullivan, and B. Shan, Comparative profiling of miRNA expression of lung adenocarcinoma cells in two-dimensional and three-dimensional cultures. Gene 511, 143 (2012).
21. A. Birgersdotter, R. Sandberg, and I. Ernberg, Gene expression perturbation in vitro - a growing case for three-dimensional (3D) culture systems. Semin. Cancer Biol. 15, 405 (2005).
22. E. Cukierman, R. Pankov, and K. M. Yamada, Cell interactions with three-dimensional matrices. Curr. Opin. Cell Biol. 14, 633 (2002).
23. C. M. Nelson and M. J. Bissell, Of extracellular matrix, scaffolds, and signaling: Tissue architecture regulates development, homeostasis, and cancer. Annu. Rev. Cell Dev. Biol. 22, 287 (2006).
24. D. K. Mishra, J. H. Sakamoto, M. J. Thrall, B. N. Baird, S. H. Blackmon, M. Ferrari, J. M. Kurie, and M. P. Kim, Human lung cancer cells grown in an ex vivo 3D lung model produce matrix metalloproteinases not produced in 2D culture. PLoS One 7, 17 (2012).
25. C. Mobley and G. Hochhaus, Methods used to assess pulmonary deposition and absorption of drugs. Drug Discov. Today 6, 367 (2001).
26. M. Sakagami, In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv. Drug Deliv. Rev. 58, 1030 (2006).
27. C. A. Fernandes and R. Vanbever, Preclinical models for pulmonary drug delivery. Expert Opin. Drug Deliv. 6, 1231 (2009).
28. R. U. Agu and M. I. Ugwoke, In vitro and in vivo testing methods for respiratory drug delivery. Expert Opin. Drug Deliv. 8, 57 (2011).
29. S. A. Cryan, N. Sivadas, and L. Garcia-Contreras, In vivo animal models for drug delivery across the lung mucosal barrier. Adv. Drug Deliv. Rev. 59, 1133 (2007).
30. B. J. Borah, S. J. Borah, and D. K. Dutta, Multifunctional phosphine stabilized gold nanoparticles: An active catalytic system for three-component coupling reaction. J. Nanosci. Nanotechnol. 13, 5080 (2013).
31. E. Morales-Avila, G. Ferro-Flores, B. E. Ocampo-García, and L. M. Gómez-Oliván, Engineered multifunctional RGD-gold nanoparticles for the detection of tumour-specific alpha(v)beta(3) expression: Chemical characterisation and ecotoxicological risk assessment. J. Biomed. Nanotechnol. 8, 991 (2012).
32. Z. G. Gao, Z. H. Jin, X. Z. Yin, and L. Tian, Multifunctional nanoparticles for targeting cancer therapy. J. Nanosci. Nanotechnol. 10, 7743 (2010).
33. P. H. Tran, T. T. Tran, T. V. Vo, C. L. Vo, and B. J. Lee, Novel multifunctional biocompatible gelatin-oleic acid conjugate: Self-assembled nanoparticles for drug delivery. J. Biomed. Nanotechnol. 9, 1416 (2013).
34. L. Thorsson, S. P. Newman, A. Weisz, E. Trofast, and F. Moren, Nasal distribution of budesonide inhaled via a powder inhaler. Rhinology 31, 7 (1993).
35. N. Sanders, C. Rudolph, K. Braeckmans, S. C. De Smedt, and J. Demeester, Extracellular barriers in respiratory gene therapy. Adv. Drug Deliv. Rev. 61, 115 (2009).
36. M. B. Antunes, D. A. Gudis, and N. A. Cohen, Epithelium, cilia, and mucus: Their importance in chronic rhinosinusitis. Immunol. Allergy Clin. North Am. 29, 631 (2009).
37. J. Rosenecker, S. Naundorf, and C. Rudolph, Airway surface liquid contains endogenous DNase activity which can be activated by exogenous magnesium. Eur. J. Med. Res. 14, 304 (2009).
38. J. Perez-Gil, Structure of pulmonary surfactant membranes and films: The role of proteins and lipid-protein interactions. Biochim. Biophys. Acta 1778, 1676 (2008).
39. J. Bastacky, C. Y. Lee, J. Goerke, H. Koushafar, D. Yager, L. Kenaga, T. P. Speed, Y. Chen, and J. A. Clements, Alveolar lining layer is thin and continuous: Low-temperature scanning electron microscopy of rat lung. J. Appl. Physiol. 79, 1615 (1985).
40. C. A. Ruge, U. F. Schaefer, J. Herrmann, J. Kirch, O. Canadas, M. Echaide, J. Perez-Gil, C. Casals, R. Muller, and C. M. Lehr, The interplay of lung surfactant proteins and lipids assimilates the macrophage clearance of nanoparticles. PLoS One. 7, 10 (2012).
41. M. Ryser, A. Burn, T. Wessel, M. Frenz, and J. Ricka, Functional imaging of mucociliary phenomena: High-speed digital reflection contrast microscopy. Eur. Biophys. J. 37, 35 (2007).
42. D. J. Smith, E. A. Gaffney, and J. R. Blake, Modelling mucociliary clearance. Respir. Physiol. Neurobiol. 163, 178 (2008).
43. M. Guilliams, B. N. Lambrecht, and H. Hammad, Division of labor between lung dendritic cells and macrophages in the defense against pulmonary infections. Mucosal Immunol. 6, 464 (2013).
44. M. Ibrahim and L. Garcia-Contreras, Mechanisms of absorption and elimination of drugs administered by inhalation. Therapeutic Deliv. 4, 1027 (2013).
45. C. J. Beadsmoore and N. J. Screaton, Classification, staging and prognosis of lung cancer. Eur. J. Radiol. 45, 8 (2003).
46. T. Naruke, T. Goya, R. Tsuchiya, and K. Suemasu, Prognosis and survival in resected lung carcinoma based on the new international staging system. J. Thorac. Cardiovasc. Surg. 96, 440 (1988).
47. C. F. Mountain, A new international staging system for lung cancer. 1986. Chest 136, e25 (2009).
48. J. Fink and A. Ari, Aerosol delivery to intubated patients. Expert Opin. Drug Deliv. 10, 1077 (2013).
49. A. L. Da Silva, R. S. Santos, D. G. Xisto, V. Alonso Sdel, M. M. Morales, and P. R. Rocco, Nanoparticle-based therapy for respiratory diseases. An. Acad. Bras. Cienc. 85, 137 (2013).
50. D. Yi and T. S. Wiedmann, Inhalation adjuvant therapy for lung cancer. J. Aerosol Med. Pulm. Drug Deliv. 23, 181 (2010).
51. J. Yu and Y. W. Chien, Pulmonary drug delivery: Physiologic and mechanistic aspects. Crit. Rev. Ther. Drug Carrier Syst. 14, 395 (1997).
52. J. Lenzer, Inhaled insulin is approved in Europe and United States. BMJ 332, 321 (2006).
53. L. Heinemann, New ways of insulin delivery. Int J Clin Pract Suppl. 170, 31 (2011).
54. M. Tobyn, J. N. Staniforth, D. Morton, Q. Harmer, and M. E. Newton, Active and intelligent inhaler device development. Int. J. Pharm. 277, 31 (2004).
55. P. R. Tuinman, B. Dixon, M. Levi, N. P. Juffermans, and M. J. Schultz, Nebulized anticoagulants for acute lung injury - A systematic review of preclinical and clinical investigations. Crit. Care 16, R70 (2012).
56. R. Siekmeier and G. Scheuch, Treatment of systemic diseases by inhalation of biomolecule aerosols. J. Physiol. Pharmacol. 5, 15 (2009).
57. J. Zhang, L. Wu, H. K. Chan, and W. Watanabe, Formation, characterization, and fate of inhaled drug nanoparticles. Adv. Drug Deliv. Rev. 63, 441 (2011).
58. D. S. Conti, B. Bharatwaj, D. Brewer, and S. R. da Rocha, Propellant-based inhalers for the non-invasive delivery of genes via oral inhalation. J. Control. Release 157, 406 (2012).
59. S. V. Fulzele, M. S. Shaik, A. Chatterjee, and M. Singh, Anticancer effect of celecoxib and aerosolized docetaxel against human non-small cell lung cancer cell line, A549. J. Pharm. Pharmacol. 58, 327 (2006).
60. M. J. Telko and A. J. Hickey, Dry powder inhaler formulation. Respir. Care 50, 1209 (2005).
61. L. D. Mastrandrea and T. Quattrin, Clinical evaluation of inhaled insulin. Adv. Drug Deliv. Rev. 58, 1061 (2006).
62. A. J. Hickey and L. Garcia-Contreras, Immunological and toxicological implications of short-term studies in animals of pharmaceutical aerosol delivery to the lungs: Relevance to humans. Crit. Rev. Ther. Drug Carrier Syst. 18, 387 (2001).
63. C. Pfeifer, G. Hasenpusch, S. Uezguen, M. K. Aneja, D. Reinhardt, J. Kirch, M. Schneider, S. Claus, W. Friess, and C. Rudolph, Dry powder aerosols of polyethylenimine (PEI)-based gene vectors mediate efficient gene delivery to the lung. J. Control. Release. 154, 69 (2011).
64. S. A. Meenach, K. W. Anderson, J. Zach Hilt, R. C. McGarry, and H. M. Mansour, Characterization and aerosol dispersion performance of advanced spray-dried chemotherapeutic PEGylated phospholipid particles for dry powder inhalation delivery in lung cancer. Eur. J. Pharm. Sci. 49, 699 (2013).
65. K. Mohri, T. Okuda, A. Mori, K. Danjo, and H. Okamoto, Optimized pulmonary gene transfection in mice by spray-freeze dried powder inhalation. J. Control Release 144, 221 (2010).
66. W. H. Roa, S. Azarmi, M. H. Al-Hallak, W. H. Finlay, A. M. Magliocco, and R. Lobenberg, Inhalable nanoparticles, a noninvasive approach to treat lung cancer in a mouse model. J. Control Release 150, 49 (2011).
67. O. Taratula, A. Kuzmov, M. Shah, O. B. Garbuzenko, and T. Minko, Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. J. Control Release 171, 349 (2013).
68. W. Liang, P. C. Kwok, M. Y. Chow, P. Tang, A. J. Mason, H. K. Chan, and J. K. Lam, Formulation of pH responsive peptides as inhalable dry powders for pulmonary delivery of nucleic acids. Eur. J. Pharm. Biopharm. 20, 00174 (2013).
69. Y. Luo, X. Zhai, C. Ma, P. Sun, Z. Fu, W. Liu, and J. Xu, An inhalable beta(2)-adrenoceptor ligand-directed guanidinylated chitosan carrier for targeted delivery of siRNA to lung. J. Control Release 162, 28 (2012).
70. E. Lemarie, L. Vecellio, J. Hureaux, C. Prunier, C. Valat, D. Grimbert, M. Boidron-Celle, B. Giraudeau, A. le Pape, E. Pichon, P. Diot, A. el Houfia, and F. Gagnadoux, Aerosolized gemcitabine in patients with carcinoma of the lung: Feasibility and safety study. J. Aerosol Med. Pulm. Drug. Deliv. 24, 261 (2011).
71. Z. Mohammadi, F. A. Dorkoosh, S. Hosseinkhani, K. Gilani, T. Amini, A. R. Najafabadi, and M. R. Tehrani, In vivo transfection study of chitosan-DNA-FAP-B nanoparticles as a new non viral vector for gene delivery to the lung. Int. J. Pharm. 421, 183 (2011).
72. N. K. Verma, K. Crosbie-Staunton, A. Satti, S. Gallagher, K. B. Ryan, T. Doody, C. McAtamney, R. MacLoughlin, P. Galvin, C. S. Burke, Y. Volkov, and Y. K. Gun'ko, Magnetic core-shell nanoparticles for drug delivery by nebulization. J. Nanobiotechnology 11, 1477 (2013).
73. M. M. Gaspar, A. Radomska, O. L. Gobbo, U. Bakowsky, M. W. Radomski, and C. Ehrhardt, Targeted delivery of transferrinconjugated liposomes to an orthotopic model of lung cancer in nude rats. J. Aerosol Med. Pulm. Drug Deliv. 25, 310 (2012).
74. J. Boe, J. H. Dennis, B. R. O'Driscoll, T. T. Bauer, M. Carone, B. Dautzenberg, P. Diot, K. Heslop, and L. Lannefors, European Respiratory Society Guidelines on the use of nebulizers. Eur. Respir. J. 18, 228 (2001).
75. R. W. Niven, A. Y. Ip, S. Mittelman, S. J. Prestrelski, and T. Arakawa, Some factors associated with the ultrasonic nebulization of proteins. Pharm. Res. 12, 53 (1995).
76. J. L. Rau, Design principles of liquid nebulization devices currently in use. Respir. Care. 47, 1257 (2002).
77. O. N. McCallion, K. M. Taylor, M. Thomas, and A. J. Taylor, Nebulization of fluids of different physicochemical properties with air-jet and ultrasonic nebulizers. Pharm. Res. 12, 1682 (1995).
78. R. Dhand, Nebulizers that use a vibrating mesh or plate with multiple apertures to generate aerosol. Respir. Care. 47, 1406 (2002).
79. A. L. Coates, Performance of PARI eFlow. J. Aerosol Med. Pulm. Drug Deliv. 23, 114; author reply 114 (2010).
80. E. R. Arulmuthu, D. J. Williams, H. Baldascini, H. K. Versteeg, and M. Hoare, Studies on aerosol delivery of plasmid DNA using a mesh nebulizer. Biotechnol Bioeng. 98, 939 (2007).
81. A. Weber, G. Morlin, M. Cohen, J. Williams-Warren, B. Ramsey, and A. Smith, Effect of nebulizer type and antibiotic concentration on device performance. Pediatric Pulmonology 23, 249 (1997).
82. W. L. Eschenbacher, H. A. Boushey, and D. Sheppard, Alteration in osmolarity of inhaled aerosols cause bronchoconstriction and cough, but absence of a permeant anion causes cough alone. Am. Rev. Respir. Dis. 129, 211 (1984).
83. A. Dunne, T. O'Hara, and J. Devane, A new approach to modelling the relationship between in vitro and in vivo drug dissolution/ absorption. Stat. Med. 18, 1865 (1999).
84. B. Zierenberg, Optimizing the in vitro performance of Respimat. J. Aerosol Med. 12, S19 (1999).
85. S. P. Newman, K. P. Steed, S. J. Reader, G. Hooper, and B. Zierenberg, Efficient delivery to the lungs of flunisolide aerosol from a new portable hand-held multidose nebulizer. J. Pharm. Sci. 85, 960 (1996).
86. S. P. Newman, J. Brown, K. P. Steed, S. J. Reader, and H. Kladders, Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines: Comparison of RESPIMAT with conventional metered-dose inhalers with and without spacer devices. Chest. 113, 957 (1998).
87. E. D. Bateman, D. Tashkin, N. Siafakas, R. Dahl, L. Towse, D. Massey, D. Pavia, and N. S. Zhong, A one-year trial of tiotropium Respimat plus usual therapy in COPD patients. Respir. Med. 104, 1460 (2010).
88. M. Hinchcliffe and L. Illum, Intranasal insulin delivery and therapy. Adv. Drug Deliv. Rev. 35, 199 (1999).
89. A. Fulton, S. T. Peters, G. A. Perkins, K. W. Jarosinski, A. Damiani, M. Brosnahan, E. L. Buckles, N. Osterrieder, and G. R. Van de Walle, Effective treatment of respiratory alphaherpesvirus infection using RNA interference. PLoS One. 4, 5 (2009).
90. B. J. Li, Q. Tang, D. Cheng, C. Qin, F. Y. Xie, Q. Wei, J. Xu, Y. Liu, B. J. Zheng, M. C. Woodle, N. Zhong, and P. Y. Lu, Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nat. Med. 11, 944 (2005).
91. T. Senoo, N. Hattori, T. Tanimoto, M. Furonaka, N. Ishikawa, K. Fujitaka, Y. Haruta, H. Murai, A. Yokoyama, and N. Kohno, Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis. Thorax. 65, 334 (2010).
92. V. Dwivedi, C. Manickam, R. Patterson, K. Dodson, M. Weeman, and G. J. Renukaradhya, Intranasal delivery of whole cell lysate of Mycobacterium tuberculosis induces protective immune responses to a modified live porcine reproductive and respiratory syndrome virus vaccine in pigs. Vaccine. 29, 4067 (2011).
93. A. Pires, A. Fortuna, G. Alves, and A. Falcao, Intranasal drug delivery: How, why and what for? J. Pharm. Pharm. Sci. 12, 288 (2009).
94. M. Howell, J. Mallela, C. Wang, S. Ravi, S. Dixit, U. Garapati, and S. Mohapatra, Manganese-loaded lipid-micellar theranostics for simultaneous drug and gene delivery to lungs. J. Control Release 167, 210 (2013).
95. X. Qian, J. M. Song, T. Melkamu, P. Upadhyaya, and F. Kassie, Chemoprevention of lung tumorigenesis by intranasally administered diindolylmethane in A/J mice. Carcinogenesis. 34, 841 (2013).
96. M. Mevel, M. Sainlos, B. Chatin, N. Oudrhiri, M. Hauchecorne, O. Lambert, J. P. Vigneron, P. Lehn, B. Pitard, and J. M. Lehn, Paromomycin and neomycin B derived cationic lipids: Synthesis and transfection studies. J. Control Release 158, 461 (2012).
97. K. Matsuo, H. Koizumi, M. Akashi, S. Nakagawa, T. Fujita, A. Yamamoto, and N. Okada, Intranasal immunization with poly(gamma-glutamic acid) nanoparticles entrapping antigenic proteins can induce potent tumor immunity. J. Control Release 152, 310 (2011).
98. Y. Shen, J. Chen, Q. Liu, C. Feng, X. Gao, L. Wang, Q. Zhang, and X. Jiang, Effect of wheat germ agglutinin density on cellular uptake and toxicity of wheat germ agglutinin conjugated PEG-PLA nanoparticles in Calu-3 cells. Int. J. Pharm. 413, 184 (2011).
99. B. Ghosn, A. Singh, M. Li, A. V. Vlassov, C. Burnett, N. Puri, and K. Roy, Efficient gene silencing in lungs and liver using imidazole-modified chitosan as a nanocarrier for small interfering RNA. Oligonucleotides 20, 163 (2010).
100. S. Zhou, S. Kawakami, F. Yamashita, and M. Hashida, Intranasal administration of CpG DNA lipoplex prevents pulmonary metastasis in mice. Cancer Lett. 287, 75 (2010).
101. B. Gutbier, S. M. Kube, K. Reppe, A. Santel, C. Lange, J. Kaufmann, N. Suttorp, and M. Witzenrath, RNAi-mediated suppression of constitutive pulmonary gene expression by small interfering RNA in mice. Pulm. Pharmacol. Ther. 23, 334 (2010).
102. J. K. Woo, D. S. Choi, H. T. Tran, B. E. Gilbert, W. K. Hong, and H. Y. Lee, Liposomal encapsulation of deguelin: Evidence for enhanced antitumor activity in tobacco carcinogen-induced and oncogenic K-ras-induced lung tumorigenesis. Cancer Prev. Res. 2, 361 (2009).
103. J. Conde, F. Tian, Y. Hernandez, C. Bao, D. Cui, K. P. Janssen, M. R. Ibarra, P. V. Baptista, T. Stoeger, and J. M. de la Fuente, In vivo tumor targeting via nanoparticle-mediated therapeutic siRNA coupled to inflammatory response in lung cancer mouse models. Biomaterials. 34, 7744 (2013).
104. G. Shim, H. W. Choi, S. Lee, J. Choi, Y. H. Yu, D. E. Park, Y. Choi, C. W. Kim, and Y. K. Oh, Enhanced intrapulmonary delivery of anticancer siRNA for lung cancer therapy using cationic ethylphosphocholine-based nanolipoplexes. Mol. Ther. 21, 816 (2013).
105. A. Kawabata, A. Baoum, N. Ohta, S. Jacquez, G. M. Seo, C. Berkland, and M. Tamura, Intratracheal administration of a nanoparticle-based therapy with the angiotensin II type 2 receptor gene attenuates lung cancer growth. Cancer Res. 72, 2057 (2012).
106. N. Allon, A. Saxena, C. Chambers, and B. P. Doctor, A new liposome-based gene delivery system targeting lung epithelial cells using endothelin antagonist. J. Control Release 160, 217 (2012).
107. A. Beyerle, A. Braun, O. Merkel, F. Koch, T. Kissel, and T. Stoeger, Comparative in vivo study of poly(ethylene imine)/siRNA complexes for pulmonary delivery in mice. J. Control Release 151, 51 (2011).
108. O. B. Garbuzenko, M. Saad, S. Betigeri, M. Zhang, A. A. Vetcher, V. A. Soldatenkov, D. C. Reimer, V. P. Pozharov, and T. Minko, Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug. Pharm. Res. 26, 382 (2009).
109. O. M. Merkel, A. Beyerle, D. Librizzi, A. Pfestroff, T. M. Behr, B. Sproat, P. J. Barth, and T. Kissel, Nonviral siRNA delivery to the lung: Investigation of PEG-PEI polyplexes and their in vivo performance. Mol. Pharm. 6, 1246 (2009).
110. K. E. Driscoll, D. L. Costa, G. Hatch, R. Henderson, G. Oberdorster, H. Salem, and R. B. Schlesinger, Intratracheal instillation as an exposure technique for the evaluation of respiratory tract toxicity: Uses and limitations. Toxicol. Sci. 55, 24 (2000).
111. M. Bivas-Benita, R. Zwier, H. E. Junginger, and G. Borchard, Noninvasive pulmonary aerosol delivery in mice by the endotracheal route. Eur. J. Pharm. Biopharm. 61, 214 (2005).
112. L. L. Booysen, L. Kalombo, E. Brooks, R. Hansen, J. Gilliland, V. Gruppo, P. Lungenhofer, B. Semete-Makokotlela, H. S. Swai, A. F. Kotze, A. Lenaerts, and L. H. du Plessis, In vivo/in vitro pharmacokinetic and pharmacodynamic study of spray-dried poly-(dl-lactic-co-glycolic) acid nanoparticles encapsulating rifampicin and isoniazid. Int. J. Pharm. 444, 10 (2013).
113. A. Monteiro, A. Afolabi, and E. Bilgili, Continuous production of drug nanoparticle suspensions via wet stirred media milling: A fresh look at the Rehbinder effect. Drug Dev. Ind. Pharm. 39, 266 (2013).
114. P. Kalantarian, A. R. Najafabadi, I. Haririan, A. Vatanara, Y. Yamini, M. Darabi, and K. Gilani, Preparation of 5-fluorouracil nanoparticles by supercritical antisolvents for pulmonary delivery. Int. J. Nanomedicine. 5, 763 (2010).
115. S. Azarmi, X. Tao, H. Chen, Z. Wang, W. H. Finlay, R. Lobenberg, and W. H. Roa, Formulation, and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles. Int J Pharm. 319, 155 (2006).
116. L. Hu, Y. Jia, and WenDing, Preparation and characterization of solid lipid nanoparticles loaded with epirubicin for pulmonary delivery. Die. Pharmazie. 65, 585 (2010).
117. S. M. Raleigh, R. D. Verschoyle, C. Bowskill, U. Pastorino, J. N. Staniforth, F. Steele, D. Dinsdale, P. Carthew, C. K. Lim, J. Silvester, and A. Gescher, Pulmonary availability of isotretinoin in rats after inhalation of a powder aerosol. Br. J. Cancer. 83, 935 (2000).
118. A. Valavanidis, K. Fiotakis, and T. Vlachogianni, Airborne particulate matter and human health: Toxicological assessment and importance of size and composition of particles for oxidative damage and carcinogenic mechanisms. J. Environ. Sci. Health C Environ. Carcinog. Ecotoxicol. Rev. 26, 339 (2008).
119. F. Zhao, Y. Zhao, Y. Liu, X. Chang, C. Chen, and Y. Zhao, Cellular uptake, intracellular trafficking, and cytotoxicity of nanomaterials. Small 7, 1322 (2011).
120. T. M. Sun, Y. C. Wang, F. Wang, J. Z. Du, C. Q. Mao, C. Y. Sun, R. Z. Tang, Y. Liu, J. Zhu, Y. H. Zhu, X. Z. Yang, and J. Wang, Cancer stem cell therapy using doxorubicin conjugated to gold nanoparticles via hydrazone bonds. Biomaterials 35, 836 (2014).
121. S. Hong, S. Park, J. Park, and J. Yi, Effect of end group modification of DNA-functionalized gold nanoparticles on cellular uptake in HepG2 cells. Colloids Surf B Biointerfaces 112, 415 (2013).
122. W. H. Chen, J. X. Chen, H. Cheng, C. S. Chen, J. Yang, X. D. Xu, Y. Wang, R. X. Zhuo, and X. Z. Zhang, A new anti-cancer strategy of damaging mitochondria by pro-apoptotic peptide functionalized gold nanoparticles. Chem. Commun. (Camb.) 49, 6403 (2013).
123. L. Karmani, D. Labar, V. Valembois, V. Bouchat, P. G. Nagaswaran, A. Bol, J. Gillart, P. Leveque, C. Bouzin, D. Bonifazi, C. Michiels, O. Feron, V. Gregoire, S. Lucas, T. Vander Borght, and B. Gallez, Antibody-functionalized nanoparticles for imaging cancer: Influence of conjugation to gold nanoparticles on the biodistribution of 89Zr-labeled cetuximab in mice. Contrast Media Mol. Imaging 8, 402 (2013).
124. M. Sharma, R. L. Salisbury, E. I. Maurer, S. M. Hussain, and C. E. Sulentic, Gold nanoparticles induce transcriptional activity of NF-kappaB in a B-lymphocyte cell line. Nanoscale 5, 3747 (2013).
125. R. Huschka, A. Barhoumi, Q. Liu, J. A. Roth, L. Ji, and N. J. Halas, Gene silencing by gold nanoshell-mediated delivery and laser-triggered release of antisense oligonucleotide and siRNA. ACS nano. 6, 7681 (2012).
126. N. Chanda, V. Kattumuri, R. Shukla, A. Zambre, K. Katti, A. Upendran, R. R. Kulkarni, P. Kan, G. M. Fent, S. W. Casteel, C. J. Smith, E. Boote, J. D. Robertson, C. Cutler, J. R. Lever, K. V. Katti, and R. Kannan, Bombesin functionalized gold nanoparticles show in vitro and in vivo cancer receptor specificity. Proc. Natl. Acad. Sci. U S A. 107, 8760 (2010).
127. M. F. McLaughlin, D. Robertson, P. H. Pevsner, J. S. Wall, S. Mirzadeh, and S. J. Kennel, LnPO4 Nanoparticles Doped with Ac-225 and Sequestered Daughters for Targeted Alpha Therapy. Cancer Biothe. Radiopharm. 29, 34 (2014).
128. H. W. Kao, Y. Y. Lin, C. C. Chen, K. H. Chi, D. C. Tien, C. C. Hsia, M. H. Lin, and H. E. Wang, Evaluation of EGFR-targeted radioimmuno-gold- nanoparticles as a theranostic agent in a tumor animal model. Bioorg. Med. Chem. Lett. 23, 3180 (2013).
129. B. G. Trewyn, S. Giri, Slowing, II, and V. S. Lin, Mesoporous silica nanoparticle based controlled release, drug delivery, and biosensor systems. Chem. Commun. (Camb.) 31, 3236 (2007).
130. S. Kwon, R. K. Singh, R. A. Perez, E. A. Abou Neel, H. W. Kim, and W. Chrzanowski, Silica-based mesoporous nanoparticles for controlled drug delivery. J. Tissue Eng. 4, 2041731413503357 (2013).
131. J. L. Vivero-Escoto, I. I. Slowing, B. G. Trewyn, and V. S. Y. Lin, Mesoporous Silica Nanoparticles for Intracellular Controlled Drug Delivery. Small 6, 1952 (2010).
132. J. Salonen, A. M. Kaukonen, J. Hirvonen, and V.-P. Lehto, Mesoporous silicon in drug delivery applications. J. Pharm. Sci. 97, 632 (2008).
133. J. Shen, G. Song, M. An, X. Li, N. Wu, K. Ruan, J. Hu, and R. Hu, The use of hollow mesoporous silica nanospheres to encapsulate bortezomib and improve efficacy for non-small cell lung cancer therapy. Biomaterials. 35, 316 (2014).
134. M. Ahamed, Silica nanoparticles-induced cytotoxicity, oxidative stress and apoptosis in cultured A431 and A549 cells. Hum. Exp. Toxicol. 32, 186 (2013).
135. W. Lin, Y. W. Huang, X. D. Zhou, and Y. Ma, In vitro toxicity of silica nanoparticles in human lung cancer cells. Toxicol. Appl. Pharmacol. 217, 252 (2006).
136. W. Sun, N. Fang, B. G. Trewyn, M. Tsunoda, Slowing, II, V. S. Lin and E. S. Yeung, Endocytosis of a single mesoporous silica nanoparticle into a human lung cancer cell observed by differential interference contrast microscopy. Anal. Bioanal. Chem. 391, 2119 (2008).
137. R. J. Wydra, A. M. Kruse, Y. Bae, K. W. Anderson, and J. Z. Hilt, Synthesis and characterization of PEG-iron oxide core-shell composite nanoparticles for thermal therapy. Mater. Sci. Eng. C Mater. Biol. Appl. 33, 4660 (2013).
138. J. Park, S. Kim, P. E. Saw, I. H. Lee, M. K. Yu, M. Kim, K. Lee, Y. C. Kim, Y. Y. Jeong, and S. Jon, Fibronectin extra domain B-specific aptide conjugated nanoparticles for targeted cancer imaging. J. Control Release 163, 111 (2012).
139. M. Mesarosova, F. Ciampor, V. Zavisova, M. Koneracka, M. Ursinyova, K. Kozics, N. Tomasovicova, A. Hashim, I. Vavra, Z. Krizanova, Z. Husekova, M. Kubovcikova, P. Kopcansky, M. Timko, and A. Gabelova, The intensity of internalization and cytotoxicity of superparamagnetic iron oxide nanoparticles with different surface modifications in human tumor and diploid lung cells. Neoplasm. 59, 584 (2012).
140. T. Sadhukha, T. S. Wiedmann, and J. Panyam, Inhalable magnetic nanoparticles for targeted hyperthermia in lung cancer therapy. Biomaterials 34, 5163 (2013).
141. C. M. Wang, M. J. Kong, and A. Q. Dong, [Magnetic liposome mediated shRNA specifically suppresses the growth of non-small cell lung cancer in vitro and in vivo]. Zhonghua yi xue za zhi. 92, 341 (2012).
142. E. K. Larsen, T. Nielsen, T. Wittenborn, L. M. Rydtoft, A. R. Lokanathan, L. Hansen, L. Ostergaard, P. Kingshott, K. A. Howard, F. Besenbacher, N. C. Nielsen, and J. Kjems, Accumulation of magnetic iron oxide nanoparticles coated with variably sized polyethylene glycol in murine tumors. Nanoscale. 4, 2352 (2012).
143. S. H. Yang, D. Heo, J. Park, S. Na, J. S. Suh, S. Haam, S. W. Park, Y. M. Huh, and J. Yang, Role of surface charge in cytotoxicity of charged manganese ferrite nanoparticles towards macrophages. Nanotechnology 23, 505702 (2012).
144. J. M. Shen, T. Yin, X. Z. Tian, F. Y. Gao, and S. Xu, Surface charge-switchable polymeric magnetic nanoparticles for the controlled release of anticancer drug. ACS Appl. Mater. Interfaces. 5, 7014 (2013).
145. F. Tewes, C. Ehrhardt, and A. M. Healy, Superparamagnetic iron oxide nanoparticles (SPIONs)-loaded Trojan microparticles for targeted aerosol delivery to the lung. Eur. J. Pharm. Biopharm. 86, 98 (2013).
146. G. Hasenpusch, J. Geiger, K. Wagner, O. Mykhaylyk, F. Wiekhorst, L. Trahms, A. Heidsieck, B. Gleich, C. Bergemann, M. K. Aneja, and C. Rudolph, Magnetized aerosols comprising superparamagnetic iron oxide nanoparticles improve targeted drug and gene delivery to the lung. Pharm. Res. 29, 1308 (2012).
147. A. A. McBride, D. N. Price, L. R. Lamoureux, A. A. Elmaoued, J. M. Vargas, N. L. Adolphi, and P. Muttil, Preparation and characterization of novel magnetic nano-in-microparticles for site-specific pulmonary drug delivery. Mol. Pharm. 10, 3574 (2013).
148. M. I. Khan, A. Mohammad, G. Patil, S. A. Naqvi, L. K. Chauhan, and I. Ahmad, Induction of ROS, mitochondrial damage and autophagy in lung epithelial cancer cells by iron oxide nanoparticles. Biomaterials. 33, 1477 (2012).
149. D. Upadhyay, S. Scalia, R. Vogel, N. Wheate, R. O. Salama, P. M. Young, D. Traini, and W. Chrzanowski, Magnetised thermo responsive lipid vehicles for targeted and controlled lung drug delivery. Pharm. Res. 29, 2456 (2012).
150. P. V. AshaRani, G. Low Kah Mun, M. P. Hande, and S. Valiyaveettil, Cytotoxicity and genotoxicity of silver nanoparticles in human cells. ACS nano. 3, 279 (2009).
151. I. Sur, M. Altunbek, M. Kahraman, and M. Culha, The influence of the surface chemistry of silver nanoparticles on cell death. Nanotechnology 23, 375102 (2012).
152. M. C. Thounaojam, R. N. Jadeja, M. Valodkar, P. S. Nagar, R. V. Devkar, and S. Thakore, Oxidative stress induced apoptosis of human lung carcinoma (A549) cells by a novel copper nanorod formulation. Food Chem. Toxicol. 49, 2990 (2011).
153. G. Hariri, M. S. Wellons, W. H. Morris, 3rd, C. M. Lukehart, and D. E. Hallahan, Multifunctional FePt nanoparticles for radiation-guided targeting and imaging of cancer. Ann. Biomed. Eng. 39, 946 (2011).
154. M. J. Akhtar, M. Ahamed, S. Kumar, M. M. Khan, J. Ahmad, and S. A. Alrokayan, Zinc oxide nanoparticles selectively induce apoptosis in human cancer cells through reactive oxygen species. Int. J. Nanomedicine. 7, 845 (2012).
155. M. Ahamed, M. J. Akhtar, M. Raja, I. Ahmad, M. K. Siddiqui, M. S. AlSalhi, and S. A. Alrokayan, ZnO nanorod-induced apoptosis in human alveolar adenocarcinoma cells via p53, survivin and bax/bcl-2 pathways: Role of oxidative stress. Nanomedicine. 7, 904 (2011).
156. M. Fakhar-e-Alam, S. M. Ali, Z. H. Ibupoto, K. Kimleang, M. Atif, M. Kashif, F. K. Loong, U. Hashim, and M. Willander, Sensitivity of A-549 human lung cancer cells to nanoporous zinc oxide conjugated with Photofrin. Lasers Med. Sci. 27, 607 (2012).
157. C. Chen, L. Hou, H. Zhang, L. Zhu, H. Zhang, C. Zhang, J. Shi, L. Wang, X. Jia, and Z. Zhang, Single-walled carbon nanotubes mediated targeted tamoxifen delivery system using aspargine-glycine-arginine peptide. J. Drug Target. 21, 809 (2013).
158. V. Castranova, P. A. Schulte, and R. D. Zumwalde, Occupational nanosafety considerations for carbon nanotubes and carbon nanofibers. Acc. Chem. Res. 46, 642 (2013).
159. J. Pauluhn, Subchronic 13-week inhalation exposure of rats to multiwalled carbon nanotubes: Toxic effects are determined by density of agglomerate structures, not fibrillar structures. Toxicol. Sci. 113, 226 (2010).
160. H. Ellinger-Ziegelbauer and J. Pauluhn, Pulmonary toxicity of multi-walled carbon nanotubes (Baytubes) relative to alpha-quartz following a single 6h inhalation exposure of rats and a 3 months post-exposure period. Toxicology 266, 16 (2009).
161. J. E. Podesta, K. T. Al-Jamal, M. A. Herrero, B. Tian, H. Ali-Boucetta, V. Hegde, A. Bianco, M. Prato, and K. Kostarelos, Antitumor activity and prolonged survival by carbon-nanotube-mediated therapeutic siRNA silencing in a human lung xenograft model. Small 5, 1176 (2009).
162. L. Tetard, A. Passian, K. T. Venmar, R. M. Lynch, B. H. Voy, G. Shekhawat, V. P. Dravid, and T. Thundat, Imaging nanoparticles in cells by nanomechanical holography. Nat. Nanotechnol. 3, 501 (2008).
163. T. Murakami, H. Sawada, G. Tamura, M. Yudasaka, S. Iijima, and K. Tsuchida, Water-dispersed single-wall carbon nanohorns as drug carriers for local cancer chemotherapy. Nanomedicine (Lon) 3, 453 (2008).
164. K. Ajima, T. Murakami, Y. Mizoguchi, K. Tsuchida, T. Ichihashi, S. Iijima, and M. Yudasaka, Enhancement of in vivo anticancer effects of cisplatin by incorporation inside single-wall carbon nanohorns. ACS nano. 2, 2057 (2008).
165. S. Ghanbarzadeh, S. Arami, Z. Pourmoazzen, and A. Khorrami, Improvement of the antiproliferative effect of Rapamycin on tumor cell lines by poly (monomethylitaconate)-based pH-sensitive, plasma stable liposomes. Colloids Surf. B Biointerfaces 115C, 323 (2013).
166. S. Barui, S. Saha, G. Mondal, S. Haseena, and A. Chaudhuri, Simultaneous delivery of doxorubicin and curcumin encapsulated in liposomes of pegylated RGDK-lipopeptide to tumor vasculature. Biomaterials 35, 1643 (2014).
167. L. Willis, D. Hayes, Jr., and H. M. Mansour, Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery. Lung 190, 251 (2012).
168. J. Duan, F. G. Vogt, X. Li, D. Hayes, Jr., and H. M. Mansour, Design, characterization, and aerosolization of organic solution advanced spray-dried moxifloxacin and ofloxacin dipalmitoylphosphatidylcholine (DPPC) microparticulate/nanoparticulate powders for pulmonary inhalation aerosol delivery. Int. J Nanomedicine. 8, 3489 (2013).
169. G. Chimote and R. Banerjee, Molecular interactions of cord factor with dipalmitoylphosphatidylcholine monolayers: Implications for lung surfactant dysfunction in pulmonary tuberculosis. Colloids Surf. B Biointerfaces 65, 120 (2008).
170. K. Anderson, K. A. Lawson, M. Simmons-Menchaca, L. Sun, B. G. Sanders, and K. Kline, Alpha-TEA plus cisplatin reduces human cisplatin-resistant ovarian cancer cell tumor burden and metastasis. Exp. Biol. Med. (Maywood, N.J.). 229, 1169 (2004).
171. A. Gautam, J. C. Waldrep, C. L. Densmore, N. Koshkina, S. Melton, L. Roberts, B. Gilbert, and V. Knight, Growth inhibition of established B16-F10 lung metastases by sequential aerosol delivery of p53 gene and 9-nitrocamptothecin. Gene Therapy 9, 353 (2002).
172. X. Li, G. F. Fu, Y. R. Fan, C. F. Shi, X. J. Liu, G. X. Xu, and J. J. Wang, Potent inhibition of angiogenesis and liver tumor growth by administration of an aerosol containing a transferrin-liposome-endostatin complex. World J. Gastroenterol. 9, 262 (2003).
173. J. Zhou, W. Y. Zhao, X. Ma, R. J. Ju, X. Y. Li, N. Li, M. G. Sun, J. F. Shi, C. X. Zhang, and W. L. Lu, The anticancer efficacy of paclitaxel liposomes modified with mitochondrial targeting conjugate in resistant lung cancer. Biomaterials 34, 3626 (2013).
174. P. Latimer, M. Menchaca, R. M. Snyder, W. Yu, B. E. Gilbert, B. G. Sanders, and K. Kline, Aerosol delivery of liposomal formulated paclitaxel and vitamin E analog reduces murine mammary tumor burden and metastases. Exp. Biol. Med. (Maywood, N.J.) 234, 1244 (2009).
175. V. Knight, N. V. Koshkina, E. Golunski, L. E. Roberts, and B. E. Gilbert, Cyclosporin A aerosol improves the anticancer effect of paclitaxel aerosol in mice. Trans. Am. Clin. Climatol. Assoc. 115, 395 (2004).
176. C. F. Verschraegen, B. E. Gilbert, E. Loyer, A. Huaringa, G. Walsh, R. A. Newman, and V. Knight, Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(s)-camptothecin in patients with advanced pulmonary malignancies. Clin. Cancer Res. 10, 2319 (2004).
177. S. Movassaghian, H. R. Moghimi, F. H. Shirazi, A. Koshkaryev, M. S. Trivedi, and V. P. Torchilin, Efficient down-regulation of PKC-alpha gene expression in A549 lung cancer cells mediated by antisense oligodeoxynucleotides in dendrosomes. Int. J. Pharm. 441, 82 (2013).
178. B. Ma, S. Zhang, H. Jiang, B. Zhao, and H. Lv, Lipoplex morphologies and their influences on transfection efficiency in gene delivery. J. Control Release 123, 184 (2007).
179. Y. Wu, M. Crawford, Y. Mao, R. J. Lee, I. C. Davis, T. S. Elton, L. J. Lee, and S. P. Nana-Sinkam, Therapeutic delivery of MicroRNA-29b by cationic lipoplexes for lung cancer. Mol. Ther. Nucleic Acids 2, e84 (2013).
180. K. A. Jinturkar, C. Anish, M. K. Kumar, T. Bagchi, A. K. Panda and A. R. Misra, Liposomal formulations of Etoposide and Docetaxel for p53 mediated enhanced cytotoxicity in lung cancer cell lines. Biomaterials 33, 2492 (2012).
181. S. Mamidi, M. Cinci, M. Hasmann, V. Fehring, and M. Kirschfink, Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab. Mol. Oncol. 7, 580 (2013).
182. C. Wang, C. Ding, M. Kong, A. Dong, J. Qian, D. Jiang, and Z. Shen, Tumor-targeting magnetic lipoplex delivery of short hairpin RNA suppresses IGF-1R overexpression of lung adenocarcinoma A549 cells in vitro and in vivo. Biochem. Biophys. Res. Commun. 410, 537 (2011).
183. C. Zhou, B. Yu, X. Yang, T. Huo, L. J. Lee, R. F. Barth, and R. J. Lee, Lipid-coated nano-calcium-phosphate (LNCP) for gene delivery. Int. J. Pharm. 392, 201 (2010).
184. Y. Zhang, W. Y. Kim, and L. Huang, Systemic delivery of gemcitabine triphosphate via LCP nanoparticles for NSCLC and pancreatic cancer therapy. Biomaterials 34, 3447 (2013).
185. Y. Yang, J. Li, F. Liu, and L. Huang, Systemic delivery of siRNA via LCP nanoparticle efficiently inhibits lung metastasis. Mol. Ther. 20, 609 (2012).
186. Z. Xu, S. Ramishetti, Y. C. Tseng, S. Guo, Y. Wang, and L. Huang, Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis. J. Control Release 172, 259 (2013).
187. S. V. Mussi, R. C. Silva, M. C. Oliveira, C. M. Lucci, R. B. Azevedo, and L. A. Ferreira, New approach to improve encapsulation and antitumor activity of doxorubicin loaded in solid lipid nanoparticles. Eur. J. Pharm. Sci. 48, 282 (2013).
188. L. G. Souza, E. J. Silva, A. L. Martins, M. F. Mota, R. C. Braga, E. M. Lima, M. C. Valadares, S. F. Taveira, and R. N. Marreto, Development of topotecan loaded lipid nanoparticles for chemical stabilization and prolonged release. Eur. J. Pharm. Biopharm. 79, 189 (2011).
189. X. Zhang, Y. Gan, L. Gan, S. Nie, and W. Pan, PEGylated nanostructured lipid carriers loaded with 10-hydroxycamptothecin: An efficient carrier with enhanced anti-tumour effects against lung cancer. J. Pharm. Pharmacol. 60, 1077 (2008).
190. A. R. Patel, M. B. Chougule, T. I. R. Patlolla, G. Wang, and M. Singh, Efficacy of aerosolized celecoxib encapsulated nanostructured lipid carrier in non-small cell lung cancer in combination with docetaxel. Pharm. Res. 30, 1435 (2013).
191. M. Dong, T. E. Murdter, C. Philippi, B. Loretz, U. F. Schaefer, C. M. Lehr, M. Schwab, and S. Ammon-Treiber, Pulmonary delivery and tissue distribution of aerosolized antisense 2'-O-Methyl RNA containing nanoplexes in the isolated perfused and ventilated rat lung. Eur. J. Pharm. Biopharm. 81, 478 (2012).
192. N. K. Verma, K. Crosbie-Staunton, A. Satti, S. Gallagher, K. B. Ryan, T. Doody, C. McAtamney, R. MacLoughlin, P. Galvin, C. S. Burke, Y. Volkov, and Y. K. Gun'ko, Magnetic core-shell nanoparticles for drug delivery by nebulization. J. Nanobiotechnology 11, 1 (2013).
193. K. M. Al-Hallak, S. Azarmi, A. Anwar-Mohamed, W. H. Roa, and R. Lobenberg, Secondary cytotoxicity mediated by alveolar macrophages: A contribution to the total efficacy of nanoparticles in lung cancer therapy? Eur. J. Pharm. Biopharm. 76, 112 (2010).
194. K. Tomoda, T. Ohkoshi, K. Hirota, G. S. Sonavane, T. Nakajima, H. Terada, M. Komuro, K. Kitazato, and K. Makino, Preparation and properties of inhalable nanocomposite particles for treatment of lung cancer. Colloids Surf. B Biointerfaces 71, 177 (2009).
195. C. L. Tseng, T. W. Wang, G. C. Dong, S. Yueh-Hsiu Wu, T. H. Young, M. J. Shieh, P. J. Lou, and F. H. Lin, Development of gelatin nanoparticles with biotinylated EGF conjugation for lung cancer targeting. Biomaterials 28, 3996 (2007).
196. A. O. Boztas, O. Karakuzu, G. Galante, Z. Ugur, F. Kocabas, C. Z. Altuntas, and A. O. Yazaydin, Synergistic Interaction of Paclitaxel and Curcumin with Cyclodextrin Polymer Complexation in Human Cancer Cells. Mol. Pharm. 10, 2676 (2013).
197. N. Rocks, S. Bekaert, I. Coia, G. Paulissen, M. Gueders, B. Evrard, J. C. Van Heugen, P. Chiap, J. M. Foidart, A. Noel, and D. Cataldo, Curcumin-cyclodextrin complexes potentiate gemcitabine effects in an orthotopic mouse model of lung cancer. Br. J. Cancer 107, 1083 (2012).
198. S. Rahman, S. Cao, K. J. Steadman, M. Wei, and H. S. Parekh, Native and beta-cyclodextrin-enclosed curcumin: Entrapment within liposomes and their in vitro cytotoxicity in lung and colon cancer. Drug Deliv. 19, 346 (2012).
199. T. Wang, C. Zhang, X. J. Liang, W. Liang, and Y. Wu, Hydroxypropyl-beta- cyclodextrin copolymers and their nanoparticles as doxorubicin delivery system. J. Pharm. Sci. 100, 1067 (2011).
200. T. Schluep, P. Gunawan, L. Ma, G. S. Jensen, J. Duringer, S. Hinton, W. Richter, and J. Hwang, Polymeric tubulysin-peptide nanoparticles with potent antitumor activity. Clin. Cancer Res. 15, 181 (2009).
201. P. Ma and R. J. Mumper, Paclitaxel nano-delivery systems: A comprehensive review. J. Nanomed. Nanotechnol. 4, 1000164 (2013).
202. L. Chen, X. Sha, X. Jiang, Y. Chen, Q. Ren, and X. Fang, Pluronic P105/F127 mixed micelles for the delivery of docetaxel against Taxol-resistant non-small cell lung cancer: Optimization and in vitro, in vivo evaluation. Int. J. Nanomedicine 8, 73 (2013).
203. S. R. Bhattarai, S. Y. Kim, K. Y. Jang, H. K. Yi, Y. H. Lee, N. Bhattarai, S. Y. Nam, D. Y. Lee, H. Y. Kim, and P. H. Hwang, Amphiphilic triblock copolymer poly(p-dioxanone-co-L-lactide)-block-poly(ethylene glycol), enhancement of gene expression and inhibition of lung metastasis by aerosol delivery. Gene Ther. 14, 476 (2007).
204. W. Song, M. Li, Z. Tang, Q. Li, Y. Yang, H. Liu, T. Duan, H. Hong and X. Chen, Methoxypoly(ethylene glycol)-block-poly(L-glutamic acid)-loaded cisplatin and a combination with iRGD for the treatment of non-small-cell lung cancers. Macromol. Biosci. 12, 1514 (2012).
205. C. Gong, Y. Xie, Q. Wu, Y. Wang, S. Deng, D. Xiong, L. Liu, M. Xiang, Z. Qian, and Y. Wei, Improving anti-tumor activity with polymeric micelles entrapping paclitaxel in pulmonary carcinoma. Nanoscale 4, 6004 (2012).
206. G. Hariri, A. D. Edwards, T. B. Merrill, J. M. Greenbaum, A. E. van der Ende, and E. Harth, Sequential targeted delivery of Paclitaxel and camptothecin using a cross-linked "nanosponge" network for lung cancer chemotherapy. Mol. Pharm. 11, 265 (2014).
207. T. U. Ly, N. Q. Tran, T. K. Hoang, K. N. Phan, H. N. Truong, and C. K. Nguyen, Pegylated dendrimer and its effect in fluorouracil loading and release for enhancing antitumor activity. J. Biomed. Nanotechnol. 9, 213 (2013).
208. J. Hu, Y. Su, H. Zhang, T. Xu, and Y. Cheng, Design of interior-functionalized fully acetylated dendrimers for anticancer drug delivery. Biomaterials 32, 9950 (2011).
209. K. Nwe, D. E. Milenic, G. L. Ray, Y. S. Kim, and M. W. Brechbiel, Preparation of cystamine core dendrimer and antibody-dendrimer conjugates for MRI angiography. Mol. Pharm. 9, 374 (2012).
210. H. Liu, M. Shen, J. Zhao, J. Zhu, T. Xiao, X. Cao, G. Zhang, and X. Shi, Facile formation of folic acid-modified dendrimer-stabilized gold-silver alloy nanoparticles for potential cellular computed tomography imaging applications. Analyst 138, 1979 (2013).
211. K. C. Sheng, M. Kalkanidis, D. S. Pouniotis, S. Esparon, C. K. Tang, V. Apostolopoulos, and G. A. Pietersz, Delivery of antigen using a novel mannosylated dendrimer potentiates immunogenicity in vitro and in vivo. Eur. J. Immunol. 38, 424 (2008).
212. V. K. Yellepeddi, A. Kumar, and S. Palakurthi, Biotinylated poly(amido)amine (PAMAM) dendrimers as carriers for drug delivery to ovarian cancer cells in vitro. Anticancer Res. 29, 2933 (2009).
213. S. H. Medina, G. Tiruchinapally, M. V. Chevliakov, Y. Y. Durmaz, R. N. Stender, W. D. Ensminger, D. S. Shewach, and M. E. Elsayed, Targeting hepatic cancer cells with pegylated dendrimers displaying N-acetylgalactosamine and SP94 peptide ligands. Adv. Healthc. Mater. 2, 1337 (2013).
214. J. Liu, J. Liu, L. Chu, Y. Wang, Y. Duan, L. Feng, C. Yang, L. Wang, and D. Kong, Novel peptide-dendrimer conjugates as drug carriers for targeting nonsmall cell lung cancer. Int. J. Nanomedicine 6, 59 (2011).
215. A. R. Menjoge, R. M. Kannan, and D. A. Tomalia, Dendrimer-based drug and imaging conjugates: Design considerations for nanomedical applications. Drug Discov. Today 15, 171 (2010).
216. S. Biswas, P. P. Deshpande, G. Navarro, N. S. Dodwadkar, and V. P. Torchilin, Lipid modified triblock PAMAM-based nanocarriers for siRNA drug co-delivery. Biomateria. 34, 1289 (2013).
217. O. Taratula, O. B. Garbuzenko, P. Kirkpatrick, I. Pandya, R. Savla, V. P. Pozharov, H. He, and T. Minko, Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery. J. Control Release 140, 284 (2009).
218. M. T. Morgan, Y. Nakanishi, D. J. Kroll, A. P. Griset, M. A. Carnahan, M. Wathier, N. H. Oberlies, G. Manikumar, M. C. Wani, and M. W. Grinstaff, Dendrimer-encapsulated camptothecins: Increased solubility, cellular uptake, and cellular retention affords enhanced anticancer activity in vitro. Cancer Res. 66, 11913 (2006).
219. H. Wang, L. Zheng, C. Peng, M. Shen, X. Shi, and G. Zhang, Folic acid-modified dendrimer-entrapped gold nanoparticles as nanoprobes for targeted CT imaging of human lung adencarcinoma. Biomaterials 34, 470 (2013).
220. N. van Zandwijk, W. J. Mooi, and S. Rodenhuis, Prognostic factors in NSCLC. Recent experiences. Lung Cancer 12, S27 (1995).
221. Z. A. Knight and K. M. Shokat, Chemical genetics: Where genetics and pharmacology meet. Cell 128, 425 (2007).
222. B. H. Gahwiler, M. Capogna, D. Debanne, R. A. McKinney, and S. M. Thompson, Organotypic slice cultures: A technique has come of age. Trends Neurosci. 20, 471 (1997).
223. T. Sakai, M. Larsen, and K. M. Yamada, Fibronectin requirement in branching morphogenesis. Nature 423, 876 (2003).
224. K. M. Yamada and E. Cukierman, Modeling tissue morphogenesis and cancer in 3D. Cell 130, 601 (2007).
225. R. Kuttan, R. D. Spall, R. C. Duhamel, I. G. Sipes, E. Meezan, and K. Brendel, Preparation and composition of alveolar extracellular matrix and incorporated basement membrane. Lung 159, 333 (1981).
226. H. C. Ott, B. Clippinger, C. Conrad, C. Schuetz, I. Pomerantseva, L. Ikonomou, D. Kotton, and J. P. Vacanti, Regeneration and orthotopic transplantation of a bioartificial lung. Nat. Med. 16, 927 (2010).
227. S. A. Mousa, M. Yalcin, D. J. Bharali, R. Meng, H. Y. Tang, H. Y. Lin, F. B. Davis, and P. J. Davis, Tetraiodothyroacetic acid and its nanoformulation inhibit thyroid hormone stimulation of non-small cell lung cancer cells in vitro and its growth in xenografts. Lung Cancer 76, 39 (2012).
228. C. Godugu, A. R. Patel, U. Desai, T. Andey, A. Sams, and M. Singh, AlgiMatrix based 3D cell culture system as an in-vitro tumor model for anticancer studies. PLoS One 8, 18 (2013).
229. L. S. Schanker, Drug absorption from the lung. Biochem. Pharmacol. 27, 381 (1978).
230. S. J. Enna and L. S. Schanker, Absorption of drugs from the rat lung. Am J Physiol. 223, 1227 (1972).
231. R. C. Lanman, R. M. Gillilan, and L. S. Schanker, Absorption of cardiac glycosides from the rat respiratory tract. J. Pharmacol. Exp. Ther. 187, 105 (1973).
232. J. A. Burton, T. H. Gardiner, and L. S. Schanker, Absorption of herbicides from the rat lung. Arch. Environ. Health. 29, 31 (1974).
233. J. A. Burton and L. S. Schanker, Absorption of sulphonamides and antitubercular drugs from the rat lung. Xenobiotica. 4, 291 (1974).
234. J. A. Burton and L. S. Schanker, Absorption of corticosteroids from the rat lung. Steroids 23, 617 (1974).
235. A. Balmain and C. C. Harris, Carcinogenesis in mouse and human cells: Parallels and paradoxes. Carcinogenesis 21, 371 (2000).
236. A. M. Malkinson, Primary lung tumors in mice as an aid for understanding, preventing, and treating human adenocarcinoma of the lung. Lung Cancer 32, 265 (2001).
237. R. B. Howard, J. B. Mullen, M. E. Pagura, and M. R. Johnston, Characterization of a highly metastatic, orthotopic lung cancer model in the nude rat. Clin. Exp. Metastasis 17, 157 (1999).
238. R. M. Hoffman, Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: A bridge to the clinic. Invest. New Drugs 17, 343 (1999).
239. M. B. Shimkin and G. D. Stoner, Lung tumors in mice: Application to carcinogenesis bioassay. Adv. Cancer Res. 21, 1 (1975).
240. S. H. Kim and C. S. Lee, Induction of benign and malignant pulmonary tumours in mice with benzo(a)pyrene. Anticancer Res. 16, 465 (1996).
241. G. D. Stoner, Lung tumors in strain A mice as a bioassay for carcinogenicity of environmental chemicals. Exp. Lung Res. 17, 405 (1991).
242. U. R. Rapp and G. J. Todaro, Generation of oncogenic mouse type C viruses: In vitro selection of carcinoma-inducing variants. Proc. Natl. Acad. Sci. USA 77, 624 (1980).
243. T. L. McLemore, J. C. Eggleston, R. H. Shoemaker, B. J. Abbott, M. E. Bohlman, M. C. Liu, D. L. Fine, J. G. Mayo, and M. R. Boyd, Comparison of intrapulmonary, percutaneous intrathoracic, and subcutaneous models for the propagation of human pulmonary and nonpulmonary cancer cell lines in athymic nude mice. Cancer Res. 48, 2880 (1988).
244. R. B. Howard, H. Chu, B. E. Zeligman, T. Marcell, P. A. Bunn, T. L. McLemore, D. W. Mulvin, M. E. Cowen, and M. R. Johnston, Irradiated nude rat model for orthotopic human lung cancers. Cancer Res. 51, 3274 (1991).
245. R. H. Hastings, D. W. Burton, R. A. Quintana, E. Biederman, A. Gujral, and L. J. Deftos, Parathyroid hormone-related protein regulates the growth of orthotopic human lung tumors in athymic mice. Cancer 92, 1402 (2001).
246. L. Kraus-Berthier, M. Jan, N. Guilbaud, M. Naze, A. Pierre, and G. Atassi, Histology and sensitivity to anticancer drugs of two human non-small cell lung carcinomas implanted in the pleural cavity of nude mice. Clin. Cancer Res. 6, 297 (2000).
247. Y. Doki, K. Murakami, T. Yamaura, S. Sugiyama, T. Misaki, and I. Saiki, Mediastinal lymph node metastasis model by orthotopic intrapulmonary implantation of Lewis lung carcinoma cells in mice. Br. J. Cancer 79, 1121 (1999).
248. H. Y. Wang, H. M. Ross, B. Ng, and M. E. Burt, Establishment of an experimental intrapulmonary tumor nodule model. Ann. Thorac. Surg. 64, 216 (1997).
249. T. Miyoshi, K. Kondo, H. Ishikura, H. Kinoshita, Y. Matsumori, and Y. Monden, SCID mouse lymphogenous metastatic model of human lung cancer constructed using orthotopic inoculation of cancer cells. Anticancer Res. 20, 161 (2000).
250. A. S. Boehle, P. Dohrmann, I. Leuschner, H. Kalthoff, and D. Henne-Bruns, An improved orthotopic xenotransplant procedure for human lung cancer in SCID bg mice. Ann. Thorac. Surg. 69, 1010 (2000).
251. I. J. Fidler, Rationale and methods for the use of nude mice to study the biology and therapy of human cancer metastasis. Cancer Metastasis Rev. 5, 29 (1986).
252. I. J. Fidler, Orthotopic implantation of human colon carcinomas into nude mice provides a valuable model for the biology and therapy of metastasis. Cancer Metastasis Rev. 10, 229 (1991).
253. I. J. Fidler, S. Naito, and S. Pathak, Orthotopic implantation is essential for the selection, growth and metastasis of human renal cell cancer in nude mice [corrected]. Cancer Metastasis Rev. 9, 149 (1990).
254. A. Onn, T. Isobe, S. Itasaka, W. Wu, M. S. O'Reilly, W. Ki Hong, I. J. Fidler, and R. S. Herbst, Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice. Clin. Cancer Res. 9, 5532 (2003).
255. D. K. Chang, P. C. Li, R. M. Lu, W. N. Jane, and H. C. Wu, Peptide-mediated liposomal Doxorubicin enhances drug delivery efficiency and therapeutic efficacy in animal models. PLoS One 8, 0083239 (2013).
256. A. R. Patel, M. B. Chougule, E. Lim, K. P. Francis, S. Safe, and M. Sachdeva, Theranostic tumor homing nanocarriers for the treatment of lung cancer. Nanomedicine 17, 00685 (2013).
257. K. Van Impe, J. Bethuyne, S. Cool, F. Impens, D. Ruano-Gallego, O. De Wever, B. Vanloo, M. Van Troys, K. Lambein, C. Boucherie, E. Martens, O. Zwaenepoel, G. Hassanzadeh-Ghassabeh, J. Vandekerckhove, K. Gevaert, L. A. Fernandez, N. N. Sanders, and J. Gettemans, A nanobody targeting the F-actin capping protein CapG restrains breast cancer metastasis. Breast Cancer Res. 15, R116 (2013).
258. S. Deshayes, H. Cabral, T. Ishii, Y. Miura, S. Kobayashi, T. Yamashita, A. Matsumoto, Y. Miyahara, N. Nishiyama, and K. Kataoka, Phenylboronic acid-installed polymeric micelles for targeting sialylated epitopes in solid tumors. J. Am. Chem. Soc. 135, 15501 (2013).
259. Y. Zhang, L. Peng, R. J. Mumper, and L. Huang, Combinational delivery of c -myc siRNA and nucleoside analogs in a single, synthetic nanocarrier for targeted cancer therapy. Biomaterials 34, 8459 (2013).
260. M. Murakami, M. J. Ernsting, E. Undzys, N. Holwell, W. D. Foltz and S. D. Li, Docetaxel conjugate nanoparticles that target alphasmooth muscle actin-expressing stromal cells suppress breast cancer metastasis. Cancer Res. 73, 4862 (2013).
261. J. Mattern, M. Bak, E. W. Hahn, and M. Volm, Human tumor xenografts as model for drug testing. Cancer Metastasis Rev. 7, 263 (1988).
262. E. Boven, B.Winograd, D. P. Berger, M. P. Dumont, B. J. Braakhuis, O. Fodstad, S. Langdon, and H. H. Fiebig, Phase II preclinical drug screening in human tumor xenografts: A first European multicenter collaborative study. Cancer Res. 52, 5940 (1992).
263. G. G. Steel, V. D. Courtenay, and M. J. Peckham, The response to chemotherapy of a variety of human tumour xenografts. Br. J. Cancer 47, 1 (1983).
264. J. I. Johnson, S. Decker, D. Zaharevitz, L. V. Rubinstein, J. M. Venditti, S. Schepartz, S. Kalyandrug, M. Christian, S. Arbuck, M. Hollingshead, and E. A. Sausville, Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br. J. Cancer. 84, 1424 (2001).
265. R. L. Brinster, H. Y. Chen, M. E. Trumbauer, M. K. Yagle, and R. D. Palmiter, Factors affecting the efficiency of introducing foreign DNA into mice by microinjecting eggs. Proc. Natl. Acad. Sci. U S A. 82, 4438 (1985).
266. J. W. Gordon and F. H. Ruddle, Gene transfer into mouse embryos: Production of transgenic mice by pronuclear injection. Methods Enzymol. 101, 411 (1983).
267. R. Jaenisch, Retroviruses and embryogenesis: Microinjection of Moloney leukemia virus into midgestation mouse embryos. Cell 19, 181 (1980).
268. R. Jaenisch, D. Jahner, P. Nobis, I. Simon, J. Lohler, K. Harbers and D. Grotkopp, Chromosomal position and activation of retroviral genomes inserted into the germ line of mice. Cell 24, 519 (1981).
269. D. Jahner and R. Jaenisch, Integration of Moloney leukaemia virus into the germ line of mice: Correlation between site of integration and virus activation. Nature 287, 456 (1980).
270. P. Soriano and R. Jaenisch, Retroviruses as probes for mammalian development: Allocation of cells to the somatic and germ cell lineages. Cell 46, 19 (1986).
271. R. Meuwissen, S. C. Linn, M. van der Valk, W. J. Mooi, and A. Berns, Mouse model for lung tumorigenesis through Cre/lox controlled sporadic activation of the K-Ras oncogene. Oncogene 20, 6551 (2001).
272. L. Johnson, K. Mercer, D. Greenbaum, R. T. Bronson, D. Crowley, D. A. Tuveson, and T. Jacks, Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature. 410, 1111 (2001).
273. H. Galski, M. Sullivan, M. C. Willingham, K. V. Chin, M. M. Gottesman, I. Pastan, and G. T. Merlino, Expression of a human multidrug resistance cDNA (MDR1) in the bone marrow of transgenic mice: Resistance to daunomycin-induced leukopenia. Mol. Cell Biol. 9, 4357 (1989).
274. R. R. Maronpot, R. D. Palmiter, R. L. Brinster, and E. P. Sandgren, Pulmonary carcinogenesis in transgenic mice. Exp. Lung Res. 17, 305 (1991).
275. K. A. Wikenheiser, J. C. Clark, R. I. Linnoila, M. T. Stahlman and J. A. Whitsett, Simian virus 40 large T antigen directed by transcriptional elements of the human surfactant protein C gene produces pulmonary adenocarcinomas in transgenic mice. Cancer Res. 52, 5342 (1992).
276. A. Sandmoller, R. Halter, G. Suske, D. Paul, and M. Beato, A transgenic mouse model for lung adenocarcinoma. Cell Growth Differ. 6, 97 (1995).